首页> 外文期刊>Antimicrobial agents and chemotherapy. >Efficacy and tolerability of antibiotic combinations in neurobrucellosis: Results of the Istanbul study
【24h】

Efficacy and tolerability of antibiotic combinations in neurobrucellosis: Results of the Istanbul study

机译:抗生素组合在神经布鲁菌病中的功效和耐受性:伊斯坦布尔研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

No data on whether brucellar meningitis or meningoencephalitis can be treated with oral antibiotics or whether an intravenous extended-spectrum cephalosporin, namely, ceftriaxone, which does not accumulate in phagocytes, should be added to the regimen exist in the literature. The aim of a study conducted in Istanbul, Turkey, was to compare the efficacy and tolerability of ceftriaxone-based antibiotic treatment regimens with those of an oral treatment protocol in patients with these conditions. This retrospective study enrolled 215 adult patients in 28 health care institutions from four different countries. The first protocol (P1) comprised ceftriaxone, rifampin, and doxycycline. The second protocol (P2) consisted of trimethoprim-sulfamethoxazole, rifampin, and doxycycline. In the third protocol (P3), the patients started with P1 and transferred to P2 when ceftriaxone was stopped. The treatment period was shorter with the regimens which included ceftriaxone (4.40 ± 2.47 months in P1, 6.52 ± 4.15 months in P2, and 5.18 ± 2.27 months in P3) (P = 0.002). In seven patients, therapy was modified due to antibiotic side effects. When these cases were excluded, therapeutic failure did not differ significantly between ceftriaxone-based regimens (n = 5/166, 3.0%) and the oral therapy (n = 4/42, 9.5%) (P = 0.084). The efficacy of the ceftriaxone-based regimens was found to be better (n = 6/166 [3.6%] versus n = 6/42 [14.3%]; P = 0.017) when a composite negative outcome (CNO; relapse plus therapeutic failure) was considered. Accordingly, CNO was greatest in P2 (14.3%, n = 6/42) compared to P1 (2.6%, n = 3/117) and P3 (6.1%, n = 3/49) (P = 0.020). Seemingly, ceftriaxone-based regimens are more successful and require shorter therapy than the oral treatment protocol.
机译:文献中没有关于是否可以通过口服抗生素治疗布鲁氏菌性脑膜炎或脑膜脑炎的数据,也没有关于在吞噬细胞中不累积的静脉内广谱头孢菌素即头孢曲松的数据。在土耳其伊斯坦布尔进行的一项研究的目的是比较以头孢曲松为基础的抗生素治疗方案与口服治疗方案在这些情况下的疗效和耐受性。这项回顾性研究招募了来自四个不同国家的28个医疗机构的215名成年患者。第一个方案(P1)包括头孢曲松,利福平和强力霉素。第二个方案(P2)由甲氧苄氨嘧啶,磺胺甲恶唑,利福平和强力霉素组成。在第三个方案(P3)中,患者从P1开始并在停止使用头孢曲松酮后转移至P2。包括头孢曲松在内的方案的治疗期较短(P1为4.40±2.47个月,P2为6.52±4.15个月,P3为5.18±2.27个月)(P = 0.002)。在7例患者中,由于抗生素副作用而改变了治疗方法。当排除这些病例时,基于头孢曲松的方案(n = 5 / 166,3.0%)和口服疗法(n = 4 / 42,9.5%)之间的治疗失败无明显差异(P = 0.084)。当复合阴性结果(CNO;复发加治疗失败)时,以头孢曲松为基础的方案的疗效更好(n = 6/166 [3.6%]比n = 6/42 [14.3%]; P = 0.017) ) 被考虑。因此,与P1(2.6%,n = 3/117)和P3(6.1%,n = 3/49)(P = 0.020)相比,P2中的CNO最大(14.3%,n = 6/42)。看来,基于头孢曲松的治疗方案比口服治疗方案更成功,需要更短的治疗。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号